TY - JOUR
T1 - Acute pericardial effusion representing the tnf-α-mediated severe inflammation but not the coronary artery outcome of Kawasaki disease
AU - Okada, S.
AU - Hasegawa, S.
AU - Suzuki, Y.
AU - Matsubara, T.
AU - Shimomura, M.
AU - Okuda, M.
AU - Ichiyama, T.
AU - Ohga, S.
N1 - Funding Information:
We thank Midori Wakabayashi (Department of Paediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan) for assistance in quality control in the cytokine assays. This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and from the Ministry of Health, Labour and Welfare of Japan.
Publisher Copyright:
© 2015 Informa Healthcare on license from Scandinavian Rheumatology Research Foundation.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Objectives: To establish the optimal inflammation control of Kawasaki disease (KD), we investigated the clinical and pathophysiological basis of pericardial effusion (PE) during the acute phase of KD. Method: Clinical and laboratory features of Japanese KD children with PE (PE group: n = 9) and without PE (non-PE group: n = 89) were studied retrospectively by using the medical records. Serum levels of soluble tumour necrosis factor receptor 1 (sTNFR1), interleukin 6 (IL-6), and vascular endothelial growth factor (VEGF) were assessed by enzymelinked immunosorbent assays (ELISAs). Results: PE group patients had coronary artery lesions (CALs) more frequently than non-PE group patients during the acute phase of KD (33% vs. 5.6%, p = 0.024). PE patients also showed lower levels of haemoglobin (p < 0.01) and serum albumin (p < 0.01) and higher platelet counts (p=0.013) than non-PE patients. The proportion of neurological symptoms, but not other manifestations, in the PE group was higher than in the non-PE group (p = 0.022). All patients survived free from coronary artery aneurisms. Serum levels of sTNFR1, but not the other cytokines, in the PE group were higher than those in the non-PE group (p < 0.001). The sTNFR1 levels correlated positively with C-reactive protein (CRP) (r = 0.30, p = 0.019) or total bilirubin (r = 0.40, p < 0.01) levels. Conclusions: Acute PE in KD patients indicated the severity of TNF-mediated vascular inflammation and concurrent CALs. According to the progression, these patients might need more targeted therapy of anti-inflammation for a better coronary outcome.
AB - Objectives: To establish the optimal inflammation control of Kawasaki disease (KD), we investigated the clinical and pathophysiological basis of pericardial effusion (PE) during the acute phase of KD. Method: Clinical and laboratory features of Japanese KD children with PE (PE group: n = 9) and without PE (non-PE group: n = 89) were studied retrospectively by using the medical records. Serum levels of soluble tumour necrosis factor receptor 1 (sTNFR1), interleukin 6 (IL-6), and vascular endothelial growth factor (VEGF) were assessed by enzymelinked immunosorbent assays (ELISAs). Results: PE group patients had coronary artery lesions (CALs) more frequently than non-PE group patients during the acute phase of KD (33% vs. 5.6%, p = 0.024). PE patients also showed lower levels of haemoglobin (p < 0.01) and serum albumin (p < 0.01) and higher platelet counts (p=0.013) than non-PE patients. The proportion of neurological symptoms, but not other manifestations, in the PE group was higher than in the non-PE group (p = 0.022). All patients survived free from coronary artery aneurisms. Serum levels of sTNFR1, but not the other cytokines, in the PE group were higher than those in the non-PE group (p < 0.001). The sTNFR1 levels correlated positively with C-reactive protein (CRP) (r = 0.30, p = 0.019) or total bilirubin (r = 0.40, p < 0.01) levels. Conclusions: Acute PE in KD patients indicated the severity of TNF-mediated vascular inflammation and concurrent CALs. According to the progression, these patients might need more targeted therapy of anti-inflammation for a better coronary outcome.
UR - http://www.scopus.com/inward/record.url?scp=84929307755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929307755&partnerID=8YFLogxK
U2 - 10.3109/03009742.2014.956140
DO - 10.3109/03009742.2014.956140
M3 - Article
C2 - 25351965
AN - SCOPUS:84929307755
SN - 0300-9742
VL - 44
SP - 247
EP - 252
JO - Scandinavian Journal of Rheumatology
JF - Scandinavian Journal of Rheumatology
IS - 3
ER -